Abstract: A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof: and relates to a pharmaceutical composition containing the same. The present invention also relates to a crystal of a compound represented by Formula (I), or a solvate thereof.

Abstract: Provided are new compounds that can have the property of being specifically taken up into cancer cells. In the present invention, novel 4-borono-phenylalanine derivatives, borono-phenylalanine derivatives having a heterocyclic skeleton, borono-phenylalanine derivatives having a fused ring structure, or pharmaceutically acceptable salts thereof are prepared. These compounds have the property of being taken up specifically by LAT1 and thus easily taken up specifically by cancer cells in the evaluation of LAT1 and LAT2 selective uptake, and can be conveniently used for neutron capture therapy and the like. A typical example is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.

Abstract: The present invention relates to a pharmaceutical composition comprising a P2X3 and/or P2X2/3 receptor antagonist for the treatment of neuropathic pain, nociceptive pain or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome. It is a pharmaceutical composition for treating and/or preventing neuropathic pain, nociceptive pain, or visceral pain, as well as interstitial cystitis and/or bladder pain syndrome, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: A novel compound having HDAC2 inhibitory activity is provided. A compound represented by Formula (I): wherein the group represented by Formula: is a group represented by Formula: or the like, wherein R3 is each independently amino or the like, and n is an integer of 0 to 4, X1 is N or the like, X2 is N or the like, R4 and R5 are each independently a hydrogen atom or the like, R1 is substituted with Substituent group C or unsubstituted non-aromatic carbocyclyl or the like, Substituent group C is halogen or the like, and R2 is a hydrogen atom, or a pharmaceutically acceptable salt thereof.

Abstract: A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof: and relates to a pharmaceutical composition containing the same. The present invention also relates to a crystal of a compound represented by Formula (I), or a solvate thereof.

Abstract: Provided is a liquid droplet collection device including: a substrate having a hydrophobic surface; and a hydrophilic channel arranged in the hydrophobic surface, wherein the hydrophilic channel includes: a first-generation channel including a plurality of tapered channel portions radially extending from an origin point and monotonically tapering with increasing distance from the origin point; and a second-generation channel that includes a plurality of tapered channel portions radially extending from an origin point and monotonically tapering with increasing distance from the origin point, and is scaled down in size as compared to the first-generation channel, wherein the second-generation channel is joined to the first-generation channel to face the same direction as the first-generation channel, and wherein one of the tapered channel portions of the second-generation channel overlaps a distal end portion of one of the tapered channel portions of the first-generation channel, and the hydrophilic channel mon

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.

Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p 1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

Abstract: A compound represented by Formula (I): wherein or the like, Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like, Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

Abstract: A compound represented by Formula (I): Chemical Formula 1 wherein Chemical Formula 2 or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is Chemical Formula 3 or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a liquid droplet collection device including: a substrate having a hydrophobic surface; and a hydrophilic channel arranged in the hydrophobic surface, wherein the hydrophilic channel includes: a first-generation channel including a plurality of tapered channel portions radially extending from an origin point and monotonically tapering with increasing distance from the origin point; and a second-generation channel that includes a plurality of tapered channel portions radially extending from an origin point and monotonically tapering with increasing distance from the origin point, and is scaled down in size as compared to the first-generation channel, wherein the second-generation channel is joined to the first-generation channel to face the same direction as the first-generation channel, and wherein one of the tapered channel portions of the second-generation channel overlaps a distal end portion of one of the tapered channel portions of the first-generation channel, and the hydrophilic channel mon

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: A heat-treatment device 10 includes a table 11 on which a ring-shaped workpiece W can be placed, and a pair of heat processing units 20 for heat-processing the peripheral surface of the workpiece W. The heat-treatment device 10 is used for obtaining the workpiece W having desired properties by the heat-processing the workpiece W while the pair of heat processing units 20 move in opposite directions along the peripheral surface of the workpiece W. The heat-treatment device 10 is configured in such a way that a pair of revolving arms 30 movable relative to the table 11 oscillate the pair of heat processing units 20 relative to the workpiece W, thereby heat-processing the peripheral surface of the workpiece W. By adopting such a configuration, it is possible to obtain a heat-treatment device heat-processing the entire circumference of a ring-shaped workpiece.

Abstract: A method for producing a negative electrode active material for a lithium ion secondary battery, comprising a step of charging either silicon and copper (II) oxide or silicon and copper metal in a pulverization device, pulverizing either the silicon and copper (II) oxide or silicon and copper metal, and simultaneously mixing either silicon and copper (II) oxide or silicon and copper metal thus pulverized. A negative electrode active material for a lithium ion secondary battery is produced by the method.

Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic activity. A compound of Formula (I): wherein Ra and Rb, and Rd and Re are taken together to form oxo or the like; R4a and R4b are hydrogen or the like; n is 1 or the like; R2 is aryl or the like; s and s? is 0 or the like; R9 and R9? are halogen or the like; R20a and R20b are hydrogen, alkyl or the like; u is 1 to 4; R13 is hydrogen or the like, or its pharmaceutically acceptable salt.

Abstract: A negative electrode active material for a lithium ion secondary battery, comprising silicon, copper and oxygen as major constitutional elements, the negative electrode active material for a lithium ion secondary battery, containing fine particles of silicon having an average crystallite diameter (Dx) measured by an X-ray diffractometry of 50 nm or less, and having elemental ratios, expressed by molar ratios, Cu/(Si+Cu+O) and O/(Si+Cu+O) of from 0.02 to 0.30, wherein the negative electrode active material contains an intermetallic compound of silicon and copper.

Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.